Eli Lilly and Co. has reached an agreement with pharmaceutical Cipla to market tirzepatide, the active ingredient in Lilly’s ...

Indian drugmaker Cipla Limited has entered into a strategic marketing and distribution agreement with US pharma major Eli ...

It comes after a Manchester Evening News investigation revealed fake versions of an experimental drug were flooding social ...

Britain's Medicines and Healthcare products Regulatory Agency seized a large cache of unlicensed weight-loss drugs, including ...

Britain's medicines regulator said on Friday it had made the world's largest seizure of unlicensed weight-loss medicines, ...

The EMA is working with social media content creators to try to encourage "safe and responsible" use of weight-loss drugs.

Mumbai, Oct. 24 -- "The introduction of a second brand of Tirzepatide in India through our commercial agreement with Cipla ...

Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.

Cipla and Eli Lilly India have announced an agreement to distribute a type 2 diabetes drug, tirzepatide, under the new brand ...

Eli Lilly ( NYSE: LLY) has partnered with India's Cipla to market its weight-loss medication Tirzepatide under a new brand in ...

Eli Lilly signed an agreement with Cipla , allowing the Indian drugmaker to sell its blockbuster weight-loss drug under a ...

Eight funds passed the screen, and these five stocks were the non-tech or tech-adjacent names with the largest cumulative ...